Related Experiment Video
Updated: Feb 27, 2026

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
Interstrand Crosslink Repair as a Target for HDAC Inhibition
Teodora Nikolova1, Nicole Kiweler1, Oliver H Krämer1
1Institute of Toxicology, University Medical Center, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.
Abstract:
DNA interstrand crosslinks (ICLs) covalently connect complementary DNA strands. Consequently, DNA replication and transcription are hampered, DNA damage responses (DDR) are initiated, and cell death is triggered. Therefore, drugs inducing ICLs are effective against rapidly growing cancer cells. However, tumors engage a complicated enzymatic machinery to repair and survive ICLs. Several factors, including the post-translational acetylation/deacetylation of lysine residues within proteins, control this network. Histone deacetylases (HDACs) modulate the expression and functions of DNA repair proteins which remove ICLs and control the accessibility of chromatin. Accordingly, histone deacetylase inhibitors (HDACi) are small, pharmacologically and clinically relevant molecules that sensitize cancer cells to ICL inducers. We discuss the mechanism of ICL repair and targets of HDACi within this pathway.
Insights
DNA interstrand crosslinks (ICLs) trigger cell death, but tumors repair them. Histone deacetylase inhibitors (HDACi) block repair pathways, making cancer cells more sensitive to ICL-inducing drugs.
Area of Science:
- Molecular Biology
- Cancer Biology
- Pharmacology
Background:
- DNA interstrand crosslinks (ICLs) covalently bind DNA strands, halting replication and transcription.
- ICLs activate DNA damage responses (DDR) and can trigger cell death, making ICL-inducing drugs effective cancer therapies.
- Tumors possess repair mechanisms to counteract ICLs, often involving enzymatic pathways and post-translational modifications like acetylation/deacetylation.
Purpose of the Study:
- To elucidate the mechanism of DNA interstrand crosslink repair.
- To identify targets of histone deacetylase inhibitors (HDACi) within the ICL repair pathway.
- To explain how HDACi sensitize cancer cells to ICL-inducing agents.
Main Methods:
- Review of ICL repair pathways.
- Analysis of histone deacetylase (HDAC) functions in DNA repair.
- Discussion of the role of HDAC inhibitors (HDACi) in cancer therapy.
Main Results:
- Histone deacetylases (HDACs) regulate DNA repair proteins involved in ICL removal.
- HDACs influence chromatin accessibility, impacting DNA repair efficiency.
- HDAC inhibitors (HDACi) target key components of the ICL repair network.
Conclusions:
- HDACs play a critical role in the enzymatic machinery that repairs DNA interstrand crosslinks.
- HDAC inhibitors represent a promising strategy to overcome tumor resistance to ICL-inducing chemotherapy.
- Targeting HDACs can enhance the efficacy of cancer treatments that rely on DNA damage induction.
More Related Videos
Related Concept Videos
Homologous Recombination
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Crossing Over
Fixing Double-strand Breaks
Inheritance of Chromatin Structures

